Patents by Inventor Solange Chamaret
Solange Chamaret has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7341731Abstract: The invention relates to a composition comprising at least one antigen, wherein the antigen is a protein or glycoprotein of a HIV-2 virus, wherein the HIV-2 virus has infectious properties with respect to human T4 lymphocytes and the essential morphological or immunological property of at least one of the retroviruses deposited at the CNCM under No. I-502, I-532, I-642, and I-643. It also relates to a process for the production of HIV-2 retrovirus antigens by lysing cells infected with the virus or lysing purified virus and recovering the antigens.Type: GrantFiled: June 27, 2002Date of Patent: March 11, 2008Assignee: Institut PasteurInventors: Luc Montagnier, Solange Chamaret, Denise Guetard, Marc Alizon, François Clavel, Mireille Guyader, Pierre Sonigo, Françoise Brun-Vezinet, Marianne Rey, Christine Rouzioux, Christine Katlama
-
Patent number: 7232654Abstract: This invention is in the field of lymphadenopathy virus, which has been designated Human Immunodeficiency Virus Type 1 (HIV-1) to detect the presence of DNA, RNA or antibodies of the lymphadenopathy retrovirus associated with the acquired immune deficiency syndrome or of the lymphadenopathy syndrome by the use of DNA fragments or the peptides encoded by said DNA fragments. The invention further relates tot he DNA fragments, vectors comprising them and the proteins expressed.Type: GrantFiled: September 19, 1994Date of Patent: June 19, 2007Assignees: Institut Pasteur, The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Jean-Claude Chermann, Solange Chamaret, Claudine Axler-Blin, Francoise Rey, Marie-Therese Nugeyre, Jacques Gruest, legal representative, Charles Dauguet, Willy Rozenbaum, Christine Rouzioux, Francois Brun-Vezinet, Luc Montagnier, Francoise Barre-Sinoussi, Pierre Tiollais, Marc Alizon, Pierre Sonigo, Simon Wain-Hobson, Stewart Cole, Oliver Danos, Robert C. Gallo, Mikulas Popovic, Mangalasseril G. Sarngadharan, Jacqueline Gruest, deceased
-
Patent number: 7217508Abstract: This invention is in the field of lymphadenopathy virus, which has been designated Human Immunodeficiency Virus Type 1 (HIV-1). This invention relates to a diagnostic means and method to detect the presence of DNA, RNA or antibodies of the lymphadenopathy retrovirus associated with the acquired immune deficiency syndrome or of the lymphadenopathy syndrome by the use of DNA fragments or the peptides encoded by said DNA fragments. The invention further relates to the DNA fragments, vectors comprising them and the proteins expressed.Type: GrantFiled: February 22, 1988Date of Patent: May 15, 2007Assignees: Institut Pasteur, The United States of America as represented by the Department of Health and Human ServicesInventors: Simon Wain-Hobson, Solange Chamaret, Claudine Axler-Blin, Francoise Rey, Marie-Therese Nugeyre, Jacques Gruest, legal representative, Charles Dauguet, Willy Rozenbaum, Christine Rouzioux, Francois Brun-Vezinet, Luc Montagnier, Jean-Claude Chermann, Francoise Barre-Sinoussi, Pierre Tiollais, Marc Alizon, Pierre Sonigo, Stewart Cole, Oliver Danos, Robert C. Gallo, Mikulas Popovic, Mangalasseril G. Sarngadharan, Jacqueline Gruest, deceased
-
Patent number: 7205102Abstract: This invention is in the field of lymphadenopathy virus which has been designated Human Immunodeficiency Virus Type 1 (HIV-1). This invention relates to a diagnostic means and method to detect the presence of DNA, RNA or antibodies of the lymphadenopathy retrovirus associated with the acquired immune deficiency syndrome or of the lymphadenopathy syndrome by the use of DNA fragments or the peptides encoded by said DNA fragments. The invention further relates to the DNA fragments, vectors comprising them and the proteins expressed.Type: GrantFiled: June 7, 1995Date of Patent: April 17, 2007Assignees: Institut Pasteur, The United States of America as Represented by the Secretary of the Department of Health and Human ServicesInventors: Luc Montagnier, Solange Chamaret, Claudine Axler-Blin, Francoise Rey, Marie-Therese Nugeyre, Jacques Gruest, legal representative, Charles Dauguet, Willy Rozenbaum, Christine Rouzioux, Francois Brun-Vezinet, Jean-Claude Chermann, Francoise Barre-Sinoussi, Robert C. Gallo, Mikulas Popovic, Mangalasseril G. Sarngadharan, Jacqueline Gruest, deceased
-
Patent number: 7122188Abstract: This invention provides antibodies which bind with p12 and p18 proteins of a human immunodeficiency virus type 1 (HIV-1), antibodies which bind with immune complexes comprising p12 or p18 proteins of HIV-1, mixtures of antibodies which bind with p12, p15, p18, p25, p36, p42, and p80 proteins of HIV-1, mixtures of antibodies which bind with immune complexes comprising the HIV-1 proteins, immune complexes comprising p12 or p18 proteins of HIV-1, and methods for production of antibodies against p2 or p18 proteins of HIV-1.Type: GrantFiled: May 26, 1993Date of Patent: October 17, 2006Assignee: Institut PasteurInventors: Luc Montagnier, Jean-Claude Chermann, Francoise Barre-Sinoussi, Francoise Vezinet-Bruil, Christine Rouzioux, Willy Rozenbaum, Charles Dauguet, Jacqueline Gruest, Marie-Theresa Nugeyre, Francoise Rey, Claudine Axler-Blin, Solange Chamaret
-
Patent number: 7115363Abstract: The invention relates to a new class of retroviruses, designated by HIV-2, of which samples have been deposited to the ECACC under numbers 87.01.1001 and 87.01.1002 and to the NCIB under numbers 12.398 and 12.399. It relates also to antigens capable to be obtained from this virus, particularly proteins p12, p16, p26 and gp140. These various antigens can be used for the diagnosis of the disease, especially by contacting these antigens with a serum of a patient submitted to the diagnosis. It relates to immunogenic compositions containing more particularly the glycoprotein gp140. Finally it concerns nucleotidic sequences, which can be used especially as hybridization probes, derived from the RNA of HIV-2.Type: GrantFiled: June 6, 1995Date of Patent: October 3, 2006Assignee: Institut PasteurInventors: Luc Montagnier, Solange Chamaret, Denise Guetard, Marc Alizon, François Clavel, Mireille Guyader, Pierre Sonigo, Francoise Brun-Vezinet, Marianne Rey, Christine Rouzioux, Christine Katlama
-
Patent number: 6664041Abstract: The invention relates to a new class of retroviruses, designated by HIV-2, of which samples have been deposited to the ECACC under numbers 87.01.1001 and 87.01.1002 and to the NCIB under numbers 12.398 and 12.399. It relates also to antigens capable to be obtained from this virus, particularly proteins p12, p16, p26 and gp140. These various antigens can be used for the diagnosis of the disease, especially by contacting these antigens with a serum of a patient submitted to the diagnosis. It relates to immunogenic compositions containing more particularly the glycoprotein gp140. Finally it concerns nucleotidic sequences, which can be used especially as hybridization probes, derived from the RNA of HIV-2.Type: GrantFiled: May 23, 2001Date of Patent: December 16, 2003Assignee: Institut PasteurInventors: Luc Montagnier, Solange Chamaret, Denise Guetard, Marc Alizon, François Clavel, Mireille Guyader, Pierre Sonigo, Françoise Brun-Vezinet, Marianne Rey, Christine Rouzioux, Christine Katlama
-
Patent number: 6627395Abstract: The identification, separation, purification, and propagation of the HIV-1 virus is provided. Moreover, the preparation of antigens from HIV-1 is further provided. The identification of HIV-1 involves the purification of a virus sample from lymphocytes and contacting the sample with antibodies, which bind to HIV-1 viruses, is provided. The propagation of HIV-1 virus involves infecting uninfected T lymphocytes with the virus. Moreover, the preparation of antigens from HIV-1 involves the separation of protein components of a purified HIV-1 virus under denaturing conditions.Type: GrantFiled: June 6, 1995Date of Patent: September 30, 2003Assignees: Institut Pasteur, The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Luc Montagnier, Jean-Claude Chermann, Francoise Barre-Sinoussi, Francoise Brun-Vezinet, Christine Rouzioux, Willy Rozenbaum, Charles Dauguet, Jacqueline Gruest, Marie-Therese Nugeyre, Francoise Rey, Claudine Axler-Blin, Solange Chamaret, Robert C. Gallo, Mikulas Popovic, Mangalasseril G. Sarngadharan
-
Publication number: 20030170658Abstract: The invention relates to a new class of retroviruses, designated by HIV-2, of which samples have been deposited to the ECACC under numbers 87.01.1001 and 87.01.1002 and to the NCIB under numbers 12.398 and 12.399.Type: ApplicationFiled: June 27, 2002Publication date: September 11, 2003Applicant: Institut PasteurInventors: Luc Montagnier, Solange Chamaret, Denise Guetard, Marc Alizon, Francois Clavel, Mireille Guyader, Pierre Sonigo, Francoise Brun-Vezinet, Marianne Rey, Christine Rouzioux, Christine Katlama
-
Patent number: 6600023Abstract: Antibodies which bind with antigens of human immunodeficiency virus type 1 (HIV-1), such as Lymphadenopathy Associated Virus (LAV), are disclosed. Retroviruses associated with Acquired Immune Deficiency Syndrome (AIDS) are isolated from the sera of patients afflicted with Lymphadenopathy Syndrome (LAS) or AIDS. Viral extracts, structural proteins and other fractions of the retrovirus immunologically recognize the sera of such patients.Type: GrantFiled: February 18, 1993Date of Patent: July 29, 2003Assignees: Institut Pasteur, The United States of America as represented by the Department of Health and Human ServicesInventors: Luc Montagnier, Jean-Claude Chermann, Francoise Barre-Sinoussi, Francoise Brun-Vezinet, Christine Rouzioux, Willy Rozenbaum, Charles Dauguet, Jacqueline Gruest, Marie-Therese Nugeyre, Francoise Rey, Claudine Axler-Blin, Solange Chamaret, Robert C. Gallo, Mikulas Popovic, Mangalasseril G. Sarngadharan
-
Patent number: 6440657Abstract: The molecular cloning and characterization of a novel human retrovirus, designated lymphadenopathy-associated virus, or LAV, is disclosed. LAV was originally isolated from a patient with acquired immune deficiency syndrome (AIDS). A cloned LAV complementary DNA (cDNA) was used to screen a library of recombinant phages constructed from the genomic DNA of LAV-infected T lymphocytes. The nucleotide sequence of an insert obtained from the recombinant phage clone &lgr;J19 was ascertained through M13 shotgun cloning and the dideoxy chain termination sequencing method. The env coding region was identified and various hydrophilic peptides obtained therefrom. These peptides correspond to amino acids 551-577, 594-603, 621-630, 657-679, and 719-758 of the LAV envelope glycoprotein. These peptides should provide suitable diagnostic reagents for the detection LAV-specific antibodies and for the generation of LAV-specific immunological reagents.Type: GrantFiled: January 6, 2000Date of Patent: August 27, 2002Assignees: Institut Pasteur, Centre National de la Recherche ScientifiqueInventors: Luc Montangnier, Bernard Krust, Solange Chamaret, François Clavel, Jean-Claude Chermann, Françoise Barre-Sinoussi, Marc Alizon, Pierre Sonigo, Stewart Cole, Olivier Danos, Simon Wain-Hobson
-
Patent number: 6428952Abstract: Retroviruses associated with Acquired Immune Deficiency Syndrome (AIDS), including Lymphadenopathy Associated Virus (LAV), are isolated from the sera of patients afflicted with Lymphadenopathy Syndrome (LAS) or AIDS. LAV is a Human Immunodeficiency Virus (HIV). Viral extract, structural proteins and other fractions of the retrovirus immunologically recongize the sera of such patients. Immunological reaction is used to detect antibodies that specifically bind to antigenic sites of the retrovirus in samples of body fluids from patients with AIDS or risk of AIDS.Type: GrantFiled: April 19, 1995Date of Patent: August 6, 2002Assignees: Institut Pasteur, The United States of America as represented by the Department of Health and Human ServicesInventors: Luc Montagnier, Jean-Claude Chermann, Francoise Barre-Sinoussi, Francoise Brun-Vezinet, Christine Rouzioux, Willy Rozenbaum, Charles Dauguet, Jacqueline Gruest, Marie-Therese Nugeyre, Francoise Rey, Claudine Axler-Blin, Solange Chamaret, Robert C. Gallo, Mikulas Popovic, G. Sarngadharan
-
Patent number: 6395495Abstract: The invention concerns a retrovirus extract containing a p25 protein which recognizes immunologically sera of patients afflicted with lymphadenopathy syndrom (LAS) or acquired immune deficiency syndrom (AIDS). It relates to a method and kit for in vivo assay of LAS or AIDS involving contacting sera from patients to be diagnosed for such diseases with said retrovirus extract and by detecting the immunological reaction, if any.Type: GrantFiled: November 10, 1999Date of Patent: May 28, 2002Assignees: Institut Pasteur, The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Luc Montagnier, Jean-Claude Chermann, Francoise Barre-Sinoussi, Christine Rouzioux, Willy Rozenbaum, Charles Dauguet, Jacqueline Gruest, Marie-Therese Nugeyre, Francoise Rey, Robert C Gallo, Mikulas Popovic, Mangalasseril G Sarngadhar, Claudine Axler-Blin, Solange Chamaret
-
Publication number: 20020051967Abstract: The invention relates to a new class of retroviruses, designated by HIV-2, of which samples have been deposited to the ECACC under numbers 87.01.1001 and 87.01.1002 and to the NCIB under numbers 12.398 and 12.399.Type: ApplicationFiled: May 23, 2001Publication date: May 2, 2002Applicant: Institut PasteurInventors: Luc Montagnier, Solange Chamaret, Denise Guetard, Marc Alizon, Francois Clavel, Mireille Guyader, Pierre Sonigo, Francoise Brun-Vezinet, Marianne Rey, Christine Rouzioux, Christine Katlama
-
Patent number: 6322964Abstract: Peptide sequences are disclosed which immunologically mimic proteins encoded by the env and gag regions of LAV-2, a retrovirus associated with AIDS. The peptide can be used in various specific binding assays to detect the presence of antibodies to LAV-2 in individuals previously exposed to the virus. The peptides enable one to distinguish the presence of antibodies to LAV-2 from antibodies to HIV-1.Type: GrantFiled: June 30, 1994Date of Patent: November 27, 2001Assignees: Genetic Systems Corporation, Institut PasteurInventors: Wesley L. Cosand, Andrew J. Watson, Raymond L. Houghton, Luc Montagnier, Marc Alizon, Solange Chamaret
-
Patent number: 6265149Abstract: The claimed invention is directed toward in vitro methods for the detection of human immunodeficiency virus type 2 (HIV-2) antibodies employing polypeptide fragments of HIV-2 Gag.Type: GrantFiled: June 6, 1995Date of Patent: July 24, 2001Assignee: Institut PasteurInventors: Luc Montagnier, Solange Chamaret, Denise Guetard, Marc Alizon, François Clavel, Mireille Guyader, Pierre Sonigo, Françoise Brun-Vezinet, Marianne Rey, Christine Rouzioux, Christine Katlama
-
Patent number: 6037165Abstract: Methods for producing the newly discovered HIV-2 retrovirus and its antigens are provided. The antigens are obtained from various HIV-2 retroviruses. The antigen compositions comprise a lysate of an HIV-2 retrovirus, a protein of an HIV-2 retrovirus, or a glycoprotein of an HIV-2 retrovirus. Specifically, the antigen composition can comprise p12, p16, p26, gp32, gp42, and gp140.Type: GrantFiled: June 6, 1995Date of Patent: March 14, 2000Assignee: Institut PasteurInventors: Luc Montagnier, Solange Chamaret, Denise Guetard, Marc Alizon, Fran.cedilla.ois Clavel, Mireille Guyader, Pierre Sonigo, Fran.cedilla.oise Brun-Vezinet, Marianne Rey, Christine Rouzioux, Christine Katlama
-
Patent number: 5843638Abstract: This invention is directed to nucleic acids derived from the pol region of the genome of human immunodeficiency virus type 1 (HIV-1). The nucleic acids are useful as probes for the detection of HIV-1. More particularly, this invention is directed to nucleic acids encoding a pol region of HIV-1 extending from about nucleotide 1856 to about 1906 and extending from about nucleotide 2048 to about nucleotide 2797.Type: GrantFiled: June 6, 1995Date of Patent: December 1, 1998Assignee: Institut Pasteur and Centre National de la Recherche ScientifiqueInventors: Luc Montagnier, Bernard Krust, Solange Chamaret, Fran.cedilla.ois Clavel, Jean-Claude Chermann, Fran.cedilla.oise Barre-Sinoussi, Marc Alizon, Pierre Sonigo, Stewart Cole, Olivier Danos, Simon Wain-Hobson
-
Patent number: 5610035Abstract: A novel human retrovirus which is the aetiological agent of acquired immune deficiency syndrome (AIDS), designated lymphadenopathy-associated virus (LAV), was isolated from the lymph nodes of a patient suffering from generalized persistant lymphadenopathy. LAV displays a tropism for CD4.sup.+ lymphocytes, a Mg.sup.2+ -dependent reverse transcriptase (RT) activity, a density of 1.16-1.17 as determined by sucrose gradient centrifugation, a particle diameter of 139 nm, and a p25 antigen that is immunologically distinct from the HTLV-I/II p24 protein. Radioimmunoprecipitation analysis (RIPA) of .sup.35 S-cysteine-labeled viral or cellular lysates employing patient antisera resulted in the identification of a viral antigen having a molecular weight of 110 kDa. Endoglycosidase treatment of this antigen produces a protein with a molecular weight of 90 kDa. Methods are disclosed for the preparation of hybridomas producing LAV gp110-specific monoclonal antibodies (Mabs).Type: GrantFiled: September 27, 1994Date of Patent: March 11, 1997Assignee: Institut Pasteur Centre National de la Recherche ScientificInventors: Luc Montagnier, Bernard Krust, Solange Chamaret, Francois Clavel, Jean-Claude Chermann, Francoise Barre-Sinoussi
-
Patent number: 5407811Abstract: This invention is directed to an isolated antibody specific for gp110 glycoprotein of a human immunodeficiency virus type 1 (HIV-1), and a hybridoma which produces such an antibody. HIV-1 is the causative agent of Acquired Immunodeficiency Syndrome (AIDS).Type: GrantFiled: September 24, 1992Date of Patent: April 18, 1995Assignee: Institut Pasteur and Centre National de la Recherche ScientificInventors: Luc Montagnier, Bernard Krust, Solange Chamaret, Francois Clavel, Jean-Claude Chermann, Francoise Barre-Sinoussi